Vascular Solutions, Inc.(Nasdaq: VASC) announced today that it has filed a patent infringementcomplaint in the U.S. District Court for the District of Minnesota againstBoston Scientific Corporation (NYSE: BSX).

Vascular Solutions (Nasdaq: VASC) announced today that it has filed a patent infringement complaint in the U.S. District Court for the District of Minnesota against Boston Scientific Corporation (NYSE: BSX).

In a report published on Wednesday, JP Morgan analyst Michael Weinstein raised the price target from $7.80 to $8.00 on Boston Scientific (NYSE: BSX) and reiterated a Neutral rating.

By Trefis: Boston Scientific's(BSX) stock rallied over 5% on Thursday after the medical devicemaker released the much-awaited four-year follow-up data from the Protect AF clinical trial pertaining to its Watchman devices. Inthis new data, Watchman ex

OrbusNeich Medical Inc. and its subsidiary, OrbusNeich Medical GmbH (collectively, "OrbusNeich"), today announced that the Dusseldorf Regional Court has issued a second preliminary injunction against the importation, distribution, sales and marketing

By SA Editor Miriam Metzinger: Stocks discussed on the in-depth session of Jim Cramer's Mad Money TV Program, Thursday May 9. Reckless Speculative Generals: Tesla (TSLA), Micron (MU), Boston Scientific (BSX), Green Mountain Coffee Roasters (GMCR), Ba

April 26 (Reuters) - April 26 (Reuters) - Boston Scientific Corp : * Credit suisse raises to outperform from neutral * Credit suisse raises target price to $8.75 from $8.50

April 26 (Reuters) - April 26 (Reuters) - Boston Scientific Corp : * Credit suisse raises to outperform from neutral * Credit suisse raises target price to $8.75 from $8.50

In the latest look at stocks ordered by largest market capitalization, Russell 3000 component Charter Communications Inc (NASD: CHTR) was identified as having a larger market cap than the smaller end of the S&P 500, for example Boston Scientific

Boston Scientific (BSX)Q1 2013 Earnings CallApril 25, 20138:00 am ETExecutivesMichael CampbellMichael F. Mahoney - Chief Executive Officer, President and DirectorJeffrey D. Capello - Chief Financial Officer and Executive Vice PresidentKenneth J. Puce

Here's your Cheat Sheet to earnings...

April 25 (Reuters) - Medical device maker Boston Scientific Corp posted a first-quarter loss on Thursday as it took $578 million in charges for litigation and restructuring, including reducing its workforce.

April 25 (Reuters) - Medical device maker Boston Scientific Corp posted a first-quarter loss on Thursday as it took $578 million in charges for litigation and restructuring, including reducing its workforce.

April 25 (Reuters) - Medical device maker Boston Scientific Corp on Thursday posted a first-quarter loss due to $578 million in restructuring, litigation and other charges.

Boston Scientific (BSX) reports its first quarter earnings on Thursday, April 25, 2013.

Boston Scientific Corporation(NYSE: BSX) has received approval by the U.S.

By Trefis: After a dismal 2012, Boston Scientific's(BSX) stock has rallied almost 25% in the past three months. Thishas been attributed mainly to apparent improvement in businessconditions for major divisions including Cardiac Rhythm Management(CRM).

Evaluation of Promus Element stent shows safety, efficacy advantages over competitor.

Boston Scientific’s Watchman may not be better than a drug that is used now to prevent strokes, heart-related deaths and blood clots in people with atrial fibrillation in the long term.

The American College of Cardiology pulled a study of the Watchman heart device from its scientific program because Boston Scientific released study data ahead of a scheduled presentation Saturday.

* Rate of death, stroke, complications within 7 days 4.6 pctvs 8.7

OrbusNeich Medical Inc. and its subsidiary, Orbus International B.V., (collectively, "OrbusNeich") today announced that they have commenced a patent infringement lawsuit in Ireland against Boston Scientific Corporation (NYSE: BSX) and two of its Iris

Quidel Corporation (QDEL)2013 Analyst & Investor Day in Boston Conference CallMarch 07, 2013, 09:30 am ETExecutivesDoug Bryant - President & CEOTim Stenzel - Chief Scientific OfficerJudi Tilghman - VP, Technology AssessmentTammi Ranalli - Senior Dire

The Boston Scientific Corporation(NYSE: BSX) PREVAIL clinical trial results will be presented in aLate-Breaking Clinical Trial presentation at the 62nd Annual ScientificSessions of the American College of Cardiology, and will include all threeco-prim

Boston Scientific Corporation (BSX)February 25, 2013 11:05 am ETExecutivesJeffrey D. Capello - Chief Financial Officer and Executive Vice PresidentMichael CampbellAnalystsMatthew J. Dodds - Citigroup Inc, Research DivisionPresentationMatthew J. Dodds

OrbusNeich today announced that OrbusNeich Medical GmbH and Orbus International B.V., subsidiaries of OrbusNeich Medical, Inc., (collectively, "OrbusNeich") have commenced patent infringement actions in Germany and The Netherlands against Boston Scie

By Trefis: Medtronic’s (MDT) stock has appreciated almost 15% this year amidst share purchases of medical device makers and has exceeded our $46 price estimate. Boston Scientific’s (BSX) earnings fueled positive sentiment regarding the overallbus

Jefferies maintained Boston Scientific Corporation (NYSE: BSX) with a Hold rating and raised the price target from $7.60 to $8.30.Jefferies noted, "Echoing a common refrain in medtech these days, the message from Boston's investor day was that stabil

Stifel Nicolaus maintained Boston Scientific Corporation (NYSE: BSX) with a Buy rating and raised the price target from $8.00 to $9.00.Stifel Nicolaus noted, "We left yesterday's Boston Scientific New York Analyst Day believing our basic thesis on BS

In a report published Wednesday, Deutsche Bank reiterated its Hold rating on Boston Scientific Corporation (NYSE: BSX), and slightly raised its price target from $6.70 to $7.20.Deutsche Bank noted, “Accelerating growth seems more credible now, but

Feb 12 (Reuters) - Medical device maker Boston ScientificCorp said it expects to grow faster than the overallmarket for implantable heart devices, which has been strugglingin recent years amid weak worldwide demand.

By Stephen Simpson:With a large number of mid-sized and large-cap med-tech companies outperforming the market over the last three months, it's fair to ask how much of Boston Scientific's (BSX) performance is based on real conviction that the company

Boston Scientific (BSX)Q4 2012 Earnings CallJanuary 29, 20138:00 am ETExecutivesMichael CampbellMichael F. Mahoney - Chief Executive Officer and PresidentJeffrey D. Capello - Chief Financial Officer and Executive Vice PresidentKen Stein - Senior Vice

A trio of health companies — Pfizer, Eli Lilly and Boston Scientific — all surge after reporting earnings

Boston Scientific plans more job cuts as the medical-device maker slowed its revenue decline in the fourth quarter.

Boston Scientific Corpreported weaker quarterly earnings on Tuesday as sales slipped and expenses rose, and the medical device maker announced more job cuts.

(Reuters) - Boston Scientific Corpreported weaker quarterly earnings on Tuesday as sales slipped and expenses rose, and the medical device maker announced more job cuts.

BOSTON (TheStreet) -- Star Scientificconfirmed Monday that Johns Hopkins Medical School has no ongoing relationship or involvement with anatabine and the human thyroiditis study. Star graciously confirmed my reporting from last week. I'm happy to see

Boston Scientific reported weaker quarterly earnings and announced that it expects to eliminate 900 to 1,000 jobs worldwide through 2013.

* Fourth-quarter net income falls to 4 cents a share from 7cents

Jan 29 (Reuters) - Boston Scientific Corp on Tuesdayposted weaker quarterly earnings as sales slipped and expensesrose.

Wall Street is optimistic about Boston Scientific (BSX), which is slated to report its fourth quarter results on Tuesday, January 29, 2013. Analysts project a profit of 11 cents a share, a rise from 9 cents per share a year ago.

By Trade In Mexico:Since August, Boston Scientific Corp. (BSX) shares have been in a trading range of around $5 to $5.80 per share, however, the stock recently broke through those levels and it now trades just over $6 per share. That could be a sign

BSX speculators scoop up February-dated calls.

CHICAGO, Jan 2 (Reuters) - Boston Scientific Corp's new leadless implantable heart defibrillator, hailed by some asa breakthrough, should be used on a limited basis until moredata are collected, a prominent cardiologist wrote in aneditorial of a top

CHICAGO, Jan 2 (Reuters) - Boston Scientific Corp's new leadless implantable heart defibrillator, hailed by some asa breakthrough, should be used on a limited basis until moredata are collected, a prominent cardiologist wrote in aneditorial of a top

ByHorizon Investments:ThesisOwing to the slowdown in the broader cardiology market, and specifically in the drug-eluting stent and implantable cardiovascular defibrillator (ICD) market, revenues for Boston Scientific Corporation (BSX) have come under

Will Boston Scientific's new pacemaker trial kickstart lagging sales?

Finding companies that have all the right stuff can produce winners.